AQR Capital Management LLC Sells 220,528 Shares of Eli Lilly and Company $LLY

AQR Capital Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 38.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 346,975 shares of the company’s stock after selling 220,528 shares during the period. AQR Capital Management LLC’s holdings in Eli Lilly and Company were worth $269,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Kaufman Rossin Wealth LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $242,000. Horizon Investments LLC raised its position in shares of Eli Lilly and Company by 6.3% in the 1st quarter. Horizon Investments LLC now owns 9,491 shares of the company’s stock valued at $7,839,000 after buying an additional 559 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,796,285 shares of the company’s stock worth $3,135,290,000 after acquiring an additional 94,078 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,027.68 on Friday. The company has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.12 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock has a fifty day simple moving average of $939.47 and a 200 day simple moving average of $818.98.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the company posted $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. Wolfe Research upped their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Sanford C. Bernstein lifted their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research report on Monday, November 24th. Finally, BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a research note on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,109.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.